Chemoinformaics analysis of 13-Tetradecanolide
| Molecular Weight | 226.36 | nRot | 0 |
| Heavy Atom Molecular Weight | 200.152 | nRig | 15 |
| Exact Molecular Weight | 226.193 | nRing | 1 |
| Solubility: LogS | -5.379 | nHRing | 1 |
| Solubility: LogP | 5.21 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 16 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 42.3206 |
| nHD | 0 | BPOL | 28.6874 |
| QED | 0.578 |
| Synth | 2.856 |
| Natural Product Likeliness | 1.11 |
| NR-PPAR-gamma | 0.773 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.43 |
| Pgp-sub | 0.001 |
| HIA | 0.002 |
| CACO-2 | -4.677 |
| MDCK | 0.0000314 |
| BBB | 0.594 |
| PPB | 0.966764 |
| VDSS | 0.921 |
| FU | 0.0239405 |
| CYP1A2-inh | 0.855 |
| CYP1A2-sub | 0.197 |
| CYP2c19-inh | 0.435 |
| CYP2c19-sub | 0.067 |
| CYP2c9-inh | 0.358 |
| CYP2c9-sub | 0.933 |
| CYP2d6-inh | 0.031 |
| CYP2d6-sub | 0.082 |
| CYP3a4-inh | 0.317 |
| CYP3a4-sub | 0.11 |
| CL | 5.135 |
| T12 | 0.463 |
| hERG | 0.029 |
| Ames | 0.008 |
| ROA | 0.021 |
| SkinSen | 0.955 |
| Carcinogencity | 0.275 |
| EI | 0.946 |
| Respiratory | 0.459 |
| NR-Aromatase | 0.063 |
| Antiviral | Yes |
| Prediction | 0.810564 |